
IRON Stock Forecast & Price Target
IRON Analyst Ratings
Bulls say
Disc Medicine is well-positioned for success with strong potential for regulatory approval of its novel treatments, including bitopertin for erythropoietic porphyrias and DISC-0974 for anemia of myelofibrosis. Positive interim data from ASCO demonstrate high response rates and rapid and sustained reductions in hepcidin and increases in serum iron. With a clear regulatory path and ongoing clinical progress, the company has a strong outlook for future revenue growth and potential earnings.
Bears say
Disc Medicine is facing a negative outlook due to FDA issuing a Complete Response Letter for their drug bitopertin, citing uncertainty in the link between the drug's biomarker change and clinical benefit despite acknowledging its effectiveness in reducing the biomarker. As a result, their ongoing Phase 3 APOLLO study has been positioned to address these concerns, with topline data expected in 4Q26 and potential approval in mid-2027. However, this delay may impact their financials, with projected sales in 2027-2030 decreasing to $5MM, $103MM, $282MM, and $503MM respectively. Overall, there is limited risk to ultimate approval, but current price action may present an attractive buying opportunity for investors looking beyond the delay.
This aggregate rating is based on analysts' research of Disc Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.
IRON Analyst Forecast & Price Prediction
Start investing in IRON
Order type
Buy in
Order amount
Est. shares
0 shares